-
By Marlene Y. Satter, AdvisorOne |
May 9, 2013
The decision by an Indian court not to grant a new patent to drug firm Novartis for a modified form of its cancer drug Glivec was a heavy blow to the company.
-
By Marlene Y. Satter, AdvisorOne |
August 30, 2012
Among the recent actions taken by the regulators were a settlement of $1.27 million to be paid by an advisory firm to 13 pension plans and charges in an insider trading ring.
-
By Savita Iyer-Ahrestani, AdvisorOne |
August 24, 2011
Conventional market wisdom has always dictated that investors who stick their necks out at a time of great crisis reap great rewards further down the line.